BIXT
Price
$0.09
Change
-$0.01 (-10.00%)
Updated
Jul 18 closing price
Capitalization
8.44M
CYTK
Price
$36.99
Change
-$0.24 (-0.64%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
4.45B
10 days until earnings call
Interact to see
Advertisement

BIXT vs CYTK

Header iconBIXT vs CYTK Comparison
Open Charts BIXT vs CYTKBanner chart's image
Bioxytran
Price$0.09
Change-$0.01 (-10.00%)
Volume$178.32K
Capitalization8.44M
Cytokinetics
Price$36.99
Change-$0.24 (-0.64%)
Volume$28K
Capitalization4.45B
BIXT vs CYTK Comparison Chart in %
Loading...
BIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIXT vs. CYTK commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIXT is a Hold and CYTK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (BIXT: $0.09 vs. CYTK: $37.23)
Brand notoriety: BIXT and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BIXT: 92% vs. CYTK: 89%
Market capitalization -- BIXT: $8.44M vs. CYTK: $4.45B
BIXT [@Biotechnology] is valued at $8.44M. CYTK’s [@Biotechnology] market capitalization is $4.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIXT’s FA Score shows that 1 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • BIXT’s FA Score: 1 green, 4 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, both BIXT and CYTK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIXT’s TA Score shows that 3 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • BIXT’s TA Score: 3 bullish, 3 bearish.
  • CYTK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than BIXT.

Price Growth

BIXT (@Biotechnology) experienced а +0.63% price change this week, while CYTK (@Biotechnology) price change was +0.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +15.57%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.45B) has a higher market cap than BIXT($8.44M). BIXT YTD gains are higher at: 5.473 vs. CYTK (-20.855). BIXT has higher annual earnings (EBITDA): -2.38M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. BIXT (4.35K). BIXT has less debt than CYTK: BIXT (1.26M) vs CYTK (791M). CYTK has higher revenues than BIXT: CYTK (19.2M) vs BIXT (0).
BIXTCYTKBIXT / CYTK
Capitalization8.44M4.45B0%
EBITDA-2.38M-513.62M0%
Gain YTD5.473-20.855-26%
P/E Ratio40.65N/A-
Revenue019.2M-
Total Cash4.35K938M0%
Total Debt1.26M791M0%
FUNDAMENTALS RATINGS
BIXT vs CYTK: Fundamental Ratings
BIXT
CYTK
OUTLOOK RATING
1..100
3650
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6561
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIXT's Valuation (1) in the null industry is significantly better than the same rating for CYTK (100) in the Biotechnology industry. This means that BIXT’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as BIXT (100) in the null industry. This means that CYTK’s stock grew similarly to BIXT’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as BIXT (100) in the null industry. This means that CYTK’s stock grew similarly to BIXT’s over the last 12 months.

CYTK's Price Growth Rating (61) in the Biotechnology industry is in the same range as BIXT (65) in the null industry. This means that CYTK’s stock grew similarly to BIXT’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for BIXT (100) in the null industry. This means that CYTK’s stock grew significantly faster than BIXT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIXTCYTK
RSI
ODDS (%)
Bullish Trend 4 days ago
60%
Bearish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bullish Trend 4 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 20 days ago
87%
Bearish Trend 22 days ago
77%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
BIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VLERF5.190.12
+2.37%
Valeura Energy Inc.
APYRF13.040.09
+0.69%
Allied Properties Real Estate Investment Trust
IAUGY27.87N/A
N/A
Insurance Australia Group Ltd.
SUNPF0.14N/A
N/A
SUN PEAK METALS CORP.
NFUNF0.22N/A
N/A
NUCLEAR FUELS INC.

BIXT and

Correlation & Price change

A.I.dvisor tells us that BIXT and CING have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIXT and CING's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIXT
1D Price
Change %
BIXT100%
-5.18%
CING - BIXT
26%
Poorly correlated
+7.48%
CYTK - BIXT
22%
Poorly correlated
-4.27%
APLM - BIXT
21%
Poorly correlated
-3.72%
ANEB - BIXT
20%
Poorly correlated
N/A
TTNP - BIXT
20%
Poorly correlated
N/A
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IMVT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-4.27%
IMVT - CYTK
53%
Loosely correlated
-2.02%
IDYA - CYTK
49%
Loosely correlated
-2.26%
KRYS - CYTK
47%
Loosely correlated
-1.77%
ROIV - CYTK
46%
Loosely correlated
-1.80%
DNLI - CYTK
44%
Loosely correlated
-3.65%
More